Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the ...

Later this month, the US Food and Drug Administration (FDA) will decide whether a new psoriasis drug, Stelara (ustekinumab), can enter the market. The human monoclonal antibody (mAb), developed by ...

An expert discusses how comparative studies of FDA-approved psoriasis biologics are crucial for treatment optimization. This study compared tildrakizumab with ustekinumab, analyzing discontinuation, ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of these two cytokines on T cells, natural killer cells, and antigen-presenting cells.

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...